Gut bacteria affect brain health, mouse study shows

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The study, by researchers at Washington University School of Medicine in St. Louis, indicates that gut bacteria produce compounds that influence the behavior of immune cells, including ones in the brain that can cause neurodegeneration. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.

Sanders-Brown director receives funding to advance work on potential drug

Linda J. Van Eldik, Ph.D., director of the University of Kentucky Sanders-Brown Center on Aging, is part of a $1.5 million grant to help further research into a possible treatment for Alzheimer’s disease. A four-year grant from the National Institute on Aging of the National Institutes of Health to Northwestern University includes a $611,676 subaward to UK. Van Eldik, the Dr. E. Vernon Smith and Eloise C. Smith Alzheimer’s Research Endowed Chair, serves as principal investigator on UK’s award.

UK HealthCare, Community Leaders Celebrate Opening of New Sanders-Brown Clinic

Today (July 25), UK HealthCare and community leaders celebrated the full opening of the Sanders-Brown Memory Clinic at Turfland. The new, larger clinic replaces the former Sanders-Brown facilities along North Broadway in Lexington.

The world looks to The University of Kentucky’s Sanders-Brown Center on Aging for answers to the mysteries of dementia, and the elderly rely on them for help in charting their path to a healthy and vigorous senior lifestyle. After outgrowing their old space, leaders at UK decided it was time that Sanders-Brown’s home for clinical research and patient care reflects their reputation — building them a new home on UK HealthCare’s Turfland Campus.

Science Snapshots: COVID-19, power outages, Alzheimer’s disease, and optical antennas

March Science Snapshots from Berkeley Lab

Nanoparticles Help Untangle Alzheimer’s Disease Amyloid Beta Plaques

ROCKVILLE, MD – Scientists are still a long way from being able to treat Alzheimer’s Disease, in part because the protein aggregates that can become brain plaques, a hallmark of the disease, are hard to study.

Nobody finds the Alzheimer’s Germ in $1 Million Challenge, but eight researchers split $200K, says Dr. Leslie Norins of Alzheimer’s Germ Quest

There is now keen interest in deeper investigation of infectious agents as the trigger of Alzheimer’s disease

Alzheimer’s Association again endorses Biogen drug despite mystery data analysis and financial conflict of interest, says Dr. Leslie Norins of Alzheimer’s Germ Quest

Although an expert FDA panel voted ten to one to withhold approval for a Biogen anti-Alzheimer’s drug candidate, the Alzheimer’s Association endorsed the compound. Serious questions have been raised about why, including conflict of interest.

University of Kentucky’s Sanders-Brown Center on Aging Facilitates First Participant in Worldwide Drug Study

Researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study. This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping this study finds that BAN2401 does just that and will ultimately help prevent Alzheimer’s disease.

Alzheimer’s study shows promise in protecting brain from tau

In the search for an Alzheimer’s cure, the scientific community has focused on drugs to lessen the buildup of amyloid protein in the brain. But new research published today in Science Translational Medicine finds that targeting tau pathology shows promise.The discovery came by looking at what could make worms resistant to pathological tau protein. That’s when researchers discovered the role of the MSUT2 gene. The latest study applied to mice as well. And held true in autopsy samples of Alzheimer’s patients.

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.